- Home
- CRGY vs MYGN Comparison
CRGY vs MYGN Comparison
Compare CRGY & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRGY
- MYGN
- Stock Information
- Founded
- CRGY 1986
- MYGN 1991
- Country
- CRGY United States
- MYGN United States
- Employees
- CRGY N/A
- MYGN N/A
- Industry
- CRGY Oil & Gas Production
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- CRGY Energy
- MYGN Health Care
- Exchange
- CRGY Nasdaq
- MYGN Nasdaq
- Market Cap
- CRGY 2.5B
- MYGN 744.7M
- IPO Year
- CRGY N/A
- MYGN 1995
- Fundamental
- Price
- CRGY $8.63
- MYGN $5.30
- Analyst Decision
- CRGY Buy
- MYGN Hold
- Analyst Count
- CRGY 12
- MYGN 15
- Target Price
- CRGY $16.40
- MYGN $15.14
- AVG Volume (30 Days)
- CRGY 3.5M
- MYGN 1.9M
- Earning Date
- CRGY 08-04-2025
- MYGN 08-05-2025
- Dividend Yield
- CRGY 5.57%
- MYGN N/A
- EPS Growth
- CRGY N/A
- MYGN N/A
- EPS
- CRGY N/A
- MYGN N/A
- Revenue
- CRGY $3,223,618,000.00
- MYGN $831,300,000.00
- Revenue This Year
- CRGY $25.73
- MYGN N/A
- Revenue Next Year
- CRGY N/A
- MYGN $6.68
- P/E Ratio
- CRGY N/A
- MYGN N/A
- Revenue Growth
- CRGY 31.58
- MYGN 7.38
- 52 Week Low
- CRGY $6.83
- MYGN $3.81
- 52 Week High
- CRGY $16.94
- MYGN $29.30
- Technical
- Relative Strength Index (RSI)
- CRGY 50.03
- MYGN 55.01
- Support Level
- CRGY $8.48
- MYGN $4.90
- Resistance Level
- CRGY $9.61
- MYGN $5.29
- Average True Range (ATR)
- CRGY 0.34
- MYGN 0.25
- MACD
- CRGY -0.06
- MYGN 0.09
- Stochastic Oscillator
- CRGY 38.36
- MYGN 93.44
About CRGY Crescent Energy Company
Crescent Energy Co is an independent energy company with a portfolio of assets in key basins across the lower 48 states. The company maintains a diverse portfolio of assets in key basins across the United States, including the Eagle Ford, Rockies, Barnett, Permian, and Mid-Con. It seeks to deliver attractive risk-adjusted investment returns and predictable cash flows across cycles with a focus on operated oil and gas assets complemented by non-operated assets, mineral and royalty interests, and midstream infrastructure.
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.